Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Kidney International

Volumn 95, Issue 2, 2019, Pages 281-295

  Rovin, Brad H ^a   Caster, Dawn J ^b   Cattran, Daniel C ^c   Gibson, Keisha L ^d   Hogan, Jonathan J ^e,k   Moeller, Marcus J ^f   Roccatello, Dario ^g   Cheung, Michael ^h   Wheeler, David C ⁱ   Winkelmayer, Wolfgang C ^j   Floege, Jürgen ^f   Adler, Sharon G ^k   Alpers, Charles E ^k   Ayoub, Isabelle ^k   Bagga, Arvind ^k   Barbour, Sean J ^k   Barratt, Jonathan ^k   Chan, Daniel T M ^k   Chang, Anthony ^k   Choo, Jason Chon Jun ^k   Cook, H Terence ^k   Coppo, Rosanna ^k   Fervenza, Fernando C ^k   Fogo, Agnes B ^k   Fox, Jonathan G ^k   Glassock, Richard J ^k   Harris, David ^k   Hodson, Elisabeth M ^k   Hoxha, Elion ^k   Iseki, Kunitoshi ^k   Jennette, J Charles ^k   Jha, Vivekanand ^k   Johnson, David W ^k   Kaname, Shinya ^k   Katafuchi, Ritsuko ^k   Kitching, A Richard ^k   Lafayette, Richard A ^k   Li, Philip K T ^k   Liew, Adrian ^k   Lv, Jicheng ^k   Malvar, Ana ^k   Maruyama, Shoichi ^k   Mejía Vilet, Juan Manuel ^k   Mok, Chi Chiu ^k   Nachman, Patrick H ^k   Nester, Carla M ^k   Noiri, Eisei ^k   O'Shaughnessy, Michelle M ^k   Özen, Seza ^k   Parikh, Samir M ^k   Park, Hyeong Cheon ^k   Peh, Chen Au ^k   Pendergraft, William F ^k   Pickering, Matthew C ^k   Pillebout, Evangéline ^k   Radhakrishnan, Jai ^k   Rathi, Manish ^k   Ronco, Pierre ^k   Smoyer, William E ^k   Tang, Sydney C W ^k   Tesař, Vladimír ^k   Thurman, Joshua M ^k   Trimarchi, Hernán ^k   Vivarelli, Marina ^k   Walters, Giles D ^k   Wang, Angela Yee Moon ^k   Wenderfer, Scott E ^k   Wetzels, Jack F M ^k   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g UNIVERSITY OF TURIN   (Italy)

^h KDIGO   (Belgium)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k NONE

more..

Author keywords

anti neutrophil cytoplasmic antibody associated vasculitis; C3 glomerulopathy; focal and segmental glomerulosclerosis; KDIGO; lupus nephritis; membranoproliferative glomerulonephritis; minimal change disease; monoclonal gammopathies of renal significance

Indexed keywords

ANTIMALARIAL AGENT; BIOLOGICAL MARKER; BORTEZOMIB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; DOUBLE STRANDED DNA; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; ATTITUDE TO HEALTH; C3 GLOMERULOPATHY; CLINICAL EVALUATION; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG MEGADOSE; ESTIMATED GLOMERULAR FILTRATION RATE; FIBRILLARY GLOMERULONEPHRITIS; FOCAL GLOMERULOSCLEROSIS; GENETIC SCREENING; GLOMERULOPATHY; HEMATURIA; HEPATITIS C; HUMAN; IDIOPATHIC DISEASE; IMMUNOMODULATION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PODOCYTOPATHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEINURIA; TREATMENT PLANNING; URINE SEDIMENT; COMPLICATION; CONSENSUS DEVELOPMENT; DISEASE EXACERBATION; GENETICS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; IMMUNOLOGY; LIPOID NEPHROSIS; NEPHROLOGY; PARAPROTEINEMIA; PATHOLOGY; PODOCYTE; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOMARKERS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE PROGRESSION; GENETIC TESTING; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; NEPHROLOGY; NEPHROSIS, LIPOID; PARAPROTEINEMIAS; PODOCYTES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85059847897     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2018.11.008     Document Type: Conference Paper

References (190)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2 (2012), 139–274.
2. Corwin, H.L., Schwartz, M.M., Lewis, E.J., The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 8 (1988), 85–89.
3. Vivarelli, M., Massella, L., Ruggiero, B., et al. Minimal change disease. Clin J Am Soc Nephrol 12 (2017), 332–345.
4. Rosenberg, A.Z., Kopp, J.B., Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 12 (2017), 502–517.
5. De Vriese, A.S., Sethi, S., Nath, K.A., et al. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J Am Soc Nephrol 29 (2018), 759–774.
6. Shalhoub, R.J., Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2 (1974), 556–560.
7. Maas, R.J., Deegens, J.K., Wetzels, J.F., Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 29 (2014), 2207–2216.
8. Hayek, S.S., Sever, S., Ko, Y.A., et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med 373 (2015), 1916–1925.
9. Clement, L.C., Avila-Casado, C., Mace, C., et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17 (2011), 117–122.
10. McCarthy, E.T., Sharma, M., Savin, V.J., Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5 (2010), 2115–2121.
11. Shin, J.I., Kronbichler, A., Rituximab for patients with nephrotic syndrome. Lancet 385 (2015), 225–226.
12. Novelli, R., Gagliardini, E., Ruggiero, B., et al. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. Am J Physiol Renal Physiol 310 (2016), F335–F341.
13. Shankland, S.J., Smeets, B., Pippin, J.W., et al. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 10 (2014), 158–173.
14. D'Agati, V.D., Fogo, A.B., Bruijn, J.A., et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43 (2004), 368–382.
15. D'Agati, V.D., Alster, J.M., Jennette, J.C., et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 8 (2013), 399–406.
16. Smeets, B., Stucker, F., Wetzels, J., et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol 184 (2014), 3239–3248.
17. Gbadegesin, R.A., Winn, M.P., Smoyer, W.E., Genetic testing in nephrotic syndrome—challenges and opportunities. Nat Rev Nephrol 9 (2013), 179–184.
18. Lovric, S., Ashraf, S., Tan, W., et al. Genetic testing in steroid-resistant nephrotic syndrome: when and how?. Nephrol Dial Transplant 31 (2016), 1802–1813.
19. Sadowski, C.E., Lovric, S., Ashraf, S., et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 26 (2015), 1279–1289.
20. Trautmann, A., Schnaidt, S., Lipska-Zietkiewicz, B.S., et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 28 (2017), 3055–3065.
21. Trautmann, A., Bodria, M., Ozaltin, F., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 10 (2015), 592–600.
22. Teeninga, N., Kist-van Holthe, J.E., van Rijswijk, N., et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 24 (2013), 149–159.
23. Sinha, A., Saha, A., Kumar, M., et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 87 (2015), 217–224.
24. Yoshikawa, N., Nakanishi, K., Sako, M., et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87 (2015), 225–232.
25. Yadav, M., Sinha, A., Hari, P., Bagga, A., Efficacy of low-dose daily versus alternate day prednisone in children with frequently relapsing nephrotic syndrome (FRNS): open-label randomized controlled trial (RCT). Abstract FP-S25-09. Pediatr Nephrol, 31, 2016, 1752.
26. Iijima, K., Sako, M., Nozu, K., et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384 (2014), 1273–1281.
27. Kim, A.H., Chung, J.J., Akilesh, S., et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight, 2, 2017 pii:81836.
28. Gellermann, J., Weber, L., Pape, L., et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24 (2013), 1689–1697.
29. Masse, V., Al Jijakli, A., Genet, P., et al. Screening and management of hepatitis B virus before the first rituximab infusion: We must do better!. Blood, 124, 2014, 2754 Available at: http://www.bloodjournal.org/content/124/21/2754. (Accessed 15 March 2018)
30. Sethi, S., Haas, M., Markowitz, G.S., et al. Mayo Clinic/Renal Pathology Society Consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 27 (2016), 1278–1287.
31. Fervenza, F.C., Sethi, S., Glassock, R.J., Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrol Dial Transplant 27 (2012), 4288–4294.
32. Nasr, S.H., Galgano, S.J., Markowitz, G.S., et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 70 (2006), 2148–2151.
33. Larsen, C.P., Ambuzs, J.M., Bonsib, S.M., et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 86 (2014), 154–161.
34. Messias, N.C., Walker, P.D., Larsen, C.P., Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 28 (2015), 854–860.
35. Larsen, C.P., Messias, N.C., Walker, P.D., et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 88 (2015), 867–873.
36. Sethi, S., Nasr, S.H., De Vriese, A.S., et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 26 (2015), 2852–2859.
37. Andeen, N.K., Yang, H.Y., Dai, D.F., et al. DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 29 (2018), 231–239.
38. Dasari, S., Alexander, M.P., Vrana, J.A., et al. DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol 29 (2018), 51–56.
39. Pickering, M.C., D'Agati, V.D., Nester, C.M., et al. C3 glomerulopathy: consensus report. Kidney Int 84 (2013), 1079–1089.
40. Goodship, T.H., Cook, H.T., Fakhouri, F., et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91 (2017), 539–551.
41. Servais, A., Noel, L.H., Roumenina, L.T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
42. Iatropoulos, P., Daina, E., Curreri, M., et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol 29 (2018), 283–294.
43. Zand, L., Kattah, A., Fervenza, F.C., et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 62 (2013), 506–514.
44. Avasare, R.S., Canetta, P.A., Bomback, A.S., et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 13 (2018), 406–413.
45. Rabasco, C., Cavero, T., Roman, E., et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88 (2015), 1153–1160.
46. Caliskan, Y., Torun, E.S., Tiryaki, T.O., et al. Immunosuppressive treatment in C3 glomerulopathy: is it really effective?. Am J Nephrol 46 (2017), 96–107.
47. Chauvet, S., Fremeaux-Bacchi, V., Petitprez, F., et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129 (2017), 1437–1447.
48. Vignon, M., Cohen, C., Faguer, S., et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int 91 (2017), 720–728.
49. Bonaud, A., Bender, S., Touchard, G., et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood 126 (2015), 757–765.
50. Bridoux, F., Javaugue, V., Bender, S., et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int 91 (2017), 423–434.
51. Cohen, C., Royer, B., Javaugue, V., et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88 (2015), 1135–1143.
52. Bridoux, F., Leung, N., Hutchison, C.A., et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87 (2015), 698–711.
53. Gumber, R., Cohen, J.B., Palmer, M.B., et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 94 (2018), 199–205.
54. Bhutani, G., Nasr, S.H., Said, S.M., et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90 (2015), 587–596.
55. Kumar, S., Paiva, B., Anderson, K.C., et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 (2016), e328–e346.
56. Comenzo, R.L., Reece, D., Palladini, G., et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26 (2012), 2317–2325.
57. Palladini, G., Dispenzieri, A., Gertz, M.A., et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30 (2012), 4541–4549.
58. Dimopoulos, M.A., Roussou, M., Gavriatopoulou, M., et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J, 7, 2017, e571.
59. Palladini, G., Hegenbart, U., Milani, P., et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124 (2014), 2325–2332.
60. Vignon, M., Javaugue, V., Alexander, M.P., et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia 31 (2017), 123–129.
61. Fermand, J.P., Bridoux, F., Kyle, R.A., et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122 (2013), 3583–3590.
62. Sawinski, D., Lim, M.A., Cohen, J.B., et al. Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis. Transplantation 102 (2018), 300–309.
63. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl 8 (2018), 91–165.
64. Levine, J.W., Gota, C., Fessler, B.J., et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32 (2005), 1164–1167.
65. Landau, D.A., Saadoun, D., Halfon, P., et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58 (2008), 604–611.
66. Ghosn, M., Palmer, M.B., Najem, C.E., et al. New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy. Clin Nephrol 87 (2017), 261–266.
67. Artemova, M., Abdurakhmanov, D., Ignatova, T., et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology 65 (2017), 1770–1771.
68. Hogan, J., Restivo, M., Canetta, P.A., et al. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant 29 (2014), 1925–1931.
69. Javaugue, V., Karras, A., Glowacki, F., et al. Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients. Am J Kidney Dis 62 (2013), 679–690.
70. Kalbermatter, S.A., Marone, C., Casartelli, D., et al. Outcome of fibrillary glomerulonephritis. Swiss Med Wkly, 142, 2012, w13578.
71. Nasr, S.H., Valeri, A.M., Cornell, L.D., et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 6 (2011), 775–784.
72. Rosenstock, J.L., Markowitz, G.S., Valeri, A.M., et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 63 (2003), 1450–1461.
73. Weening, J.J., D'Agati, V.D., Schwartz, M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 (2004), 521–530.
74. Yu, F., Wu, L.H., Tan, Y., et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 77 (2010), 820–829.
75. Wu, L.H., Yu, F., Tan, Y., et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 83 (2013), 715–723.
76. Hu, W., Chen, Y., Wang, S., et al. Clinical-morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol 11 (2016), 585–592.
77. Yu, F., Haas, M., Glassock, R., et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13 (2017), 483–495.
78. Yu, F., Tan, Y., Liu, G., et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 76 (2009), 307–317.
79. Hsieh, C., Chang, A., Brandt, D., et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 63 (2011), 865–874.
80. Mejia-Vilet, J.M., Cordova-Sanchez, B.M., Uribe-Uribe, N.O., et al. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus 26 (2017), 1042–1050.
81. Haring, C.M., Rietveld, A., van den Brand, J.A., et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 23 (2012), 149–154.
82. Schwartz, M.M., Korbet, S.M., Lewis, E.J., et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 23 (2008), 1298–1306.
83. Bajema, I.M., Wilhelmus, S., Alpers, C.E., et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93 (2018), 789–796.
84. Petri, M., Orbai, A.M., Alarcon, G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (2012), 2677–2686.
85. Rijnink, E.C., Teng, Y.K.O., Kraaij, T., et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int 93 (2018), 214–220.
86. Tsokos, G.C., Systemic lupus erythematosus. N Engl J Med 365 (2011), 2110–2121.
87. Munroe, M.E., James, J.A., Genetics of lupus nephritis: clinical implications. Semin Nephrol 35 (2015), 396–409.
88. Caster, D.J., Korte, E.A., Nanda, S.K., et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol 24 (2013), 1743–1754.
89. Bomback, A.S., Gharavi, A.G., Lupus nephritis: ancestry, genetic risk and health disparities. Nat Rev Nephrol 9 (2013), 699–700.
90. Ceccarelli, F., Perricone, C., Borgiani, P., et al. Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res, 2015, 745647.
91. Freedman, B.I., Langefeld, C.D., Andringa, K.K., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66 (2014), 390–396.
92. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
93. Condon, M.B., Ashby, D., Pepper, R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72 (2013), 1280–1286.
94. Malvar, A., Pirruccio, P., Alberton, V., et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32 (2017), 1338–1344.
95. Parikh, S.V., Alvarado, A., Malvar, A., et al. The kidney biopsy in lupus nephritis: past, present, and future. Semin Nephrol 35 (2015), 465–477.
96. Alvarado, A.S., Malvar, A., Lococo, B., et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 23 (2014), 840–847.
97. Zickert, A., Sundelin, B., Svenungsson, E., et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med, 1, 2014, e000018.
98. Dall'Era, M., Cisternas, M.G., Smilek, D.E., et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67 (2015), 1305–1313.
99. Tamirou, F., D'Cruz, D., Sangle, S., et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75 (2016), 526–531.
100. Ugolini-Lopes, M.R., Seguro, L.P.C., Castro, M.X.F., et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?. Lupus Sci Med, 4, 2017, e000213.
101. Birmingham, D.J., Shidham, G., Perna, A., et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis 73 (2014), 475–476.
102. Yang, X.W., Tan, Y., Yu, F., et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 27 (2012), 3552–3559.
103. Orbai, A.M., Truedsson, L., Sturfelt, G., et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24 (2015), 42–49.
104. Soliman, S., Mohan, C., Lupus nephritis biomarkers. Clin Immunol 185 (2017), 10–20.
105. Phatak, S., Chaurasia, S., Mishra, S.K., et al. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 187 (2017), 376–382.
106. Xuejing, Z., Jiazhen, T., Jun, L., et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol, 2012, 2012, 359647.
107. Reyes-Thomas, J., Blanco, I., Putterman, C., Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 40 (2011), 138–150.
108. Parikh, S.V., Malvar, A., Song, H., et al. Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. Transl Res 182 (2017), 1–13.
109. Parikh, S.V., Malvar, A., Song, H., et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med, 2, 2015, e000112.
110. Banchereau, R., Hong, S., Cantarel, B., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165 (2016), 551–565.
111. Pons-Estel, G.J., Alarcon, G.S., Burgos, P.I., et al. Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus 22 (2013), 899–907.
112. Ugarte-Gil, M.F., Wojdyla, D., Pastor-Asurza, C.A., et al. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus 27 (2018), 536–544.
113. Fessler, B.J., Alarcon, G.S., McGwin, G. Jr., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52 (2005), 1473–1480.
114. Galindo-Izquierdo, M., Rodriguez-Almaraz, E., Pego-Reigosa, J.M., et al. Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine, 95, 2016, e2891.
115. Joo, Y.B., Won, S., Choi, C.B., et al. Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. Lupus 26 (2017), 598–605.
116. Sciascia, S., Mompean, E., Radin, M., et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig 37 (2017), 519–524.
117. Roccatello, D., Sciascia, S., Baldovino, S., et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev 14 (2015), 1123–1130.
118. Ruiz-Irastorza, G., Ugarte, A., Saint-Pastou Terrier, C., et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 16 (2017), 826–832.
119. Liu, Z., Zhang, H., Liu, Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162 (2015), 18–26.
120. Zhang, H., Liu, Z., Zhou, M., et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 28 (2017), 3671–3678.
121. Dooley, M.A., Jayne, D., Ginzler, E.M., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 (2011), 1886–1895.
122. Houssiau, F.A., D'Cruz, D., Sangle, S., et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69 (2010), 2083–2089.
123. Lenz, O., Waheed, A.A., Baig, A., et al. Lupus nephritis: maintenance therapy for lupus nephritis: Do we now have a plan?. Clin J Am Soc Nephrol 8 (2013), 162–171.
124. Moroni, G., Gallelli, B., Quaglini, S., et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 21 (2006), 1541–1548.
125. Grootscholten, C., Berden, J.H., Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol Dial Transplant 21 (2006), 1465–1469.
126. Ioannidis, J.P., Boki, K.A., Katsorida, M.E., et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57 (2000), 258–264.
127. Mok, C.C., Ying, K.Y., Tang, S., et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50 (2004), 2559–2568.
128. Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
129. Duxbury, B., Combescure, C., Chizzolini, C., Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 22 (2013), 1489–1503.
130. Shamliyan, T.A., Dospinescu, P., Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: a systematic review and meta-analysis. Clin Ther 39 (2017), 1479–1506.
131. Moroni, G., Raffiotta, F., Trezzi, B., et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 53 (2014), 1570–1577.
132. Mok, C.C., Yap, D.Y., Navarra, S.V., et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis 16 (2013), 625–636.
133. Chavarot, N., Verhelst, D., Pardon, A., et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine, 96, 2017, e7429.
134. Song, D., Wu, L.H., Wang, F.M., et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther, 15, 2013, R12.
135. Pattanashetti, N., Anakutti, H., Ramachandran, R., et al. Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis. Kidney Int Rep 2 (2017), 844–849.
136. Chen, M.H., Chen, M.H., Chen, W.S., et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology 50 (2011), 768–775.
137. Kronbichler, A., Brezina, B., Quintana, L.F., et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 15 (2016), 38–49.
138. Sciascia, S., Radin, M., Yazdany, J., et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 37 (2017), 1249–1255.
139. de Holanda, M.I., Porto, L.C., Wagner, T., et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review. Clin Rheumatol 36 (2017), 2859–2867.
140. Legendre, C.M., Licht, C., Muus, P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
141. Licht, C., Greenbaum, L.A., Muus, P., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
142. Erkan, D., Aguiar, C.L., Andrade, D., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696.
143. Bienaime, F., Legendre, C., Terzi, F., et al. Antiphospholipid syndrome and kidney disease. Kidney Int 91 (2017), 34–44.
144. Canaud, G., Bienaime, F., Tabarin, F., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371 (2014), 303–312.
145. Webster, P., Wardle, A., Bramham, K., et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 23 (2014), 1192–1196.
146. O'Shaughnessy, M.M., Liu, S., Montez-Rath, M.E., et al. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 28 (2017), 632–644.
147. Yu, T.M., Chen, Y.H., Lan, J.L., et al. Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation. Lupus 17 (2008), 687–694.
148. Yu, T.M., Wen, M.C., Li, C.Y., et al. Impact of recurrent lupus nephritis on lupus kidney transplantation: a 20-year single center experience. Clin Rheumatol 31 (2012), 705–710.
149. Naranjo-Escobar, J., Manzi, E., Posada, J.G., et al. Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience. Lupus 26 (2017), 1157–1165.
150. Contreras, G., Mattiazzi, A., Guerra, G., et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 21 (2010), 1200–1207.
151. Briganti, E.M., Russ, G.R., McNeil, J.J., et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347 (2002), 103–109.
152. Mina, R., von Scheven, E., Ardoin, S.P., et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64 (2012), 375–383.
153. Hugle, B., Silverman, E.D., Tyrrell, P.N., et al. Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatr Nephrol 30 (2015), 113–121.
154. Pereira, M., Muscal, E., Eldin, K., et al. Clinical presentation and outcomes of childhood-onset membranous lupus nephritis. Pediatr Nephrol 32 (2017), 2283–2291.
155. Groot, N., de Graeff, N., Marks, S.D., et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76 (2017), 1965–1973.
156. Jennette, J.C., Nachman, P.H., ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 12 (2017), 1680–1691.
157. Roth, A.J., Ooi, J.D., Hess, J.J., et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 123 (2013), 1773–1783.
158. Lionaki, S., Blyth, E.R., Hogan, S.L., et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64 (2012), 3452–3462.
159. Walsh, M., Flossmann, O., Berden, A., et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64 (2012), 542–548.
160. Lyons, P.A., Rayner, T.F., Trivedi, S., et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367 (2012), 214–223.
161. Schreiber, A., Xiao, H., Jennette, J.C., et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20 (2009), 289–298.
162. Caster, D.J., Powell, D.W., Miralda, I., et al. Re-examining neutrophil participation in GN. J Am Soc Nephrol 28 (2017), 2275–2289.
163. Diaz-Crespo, F., Villacorta, J., Acevedo, M., et al. The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 52 (2016), 119–127.
164. Tomasson, G., Grayson, P.C., Mahr, A.D., et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis: a meta-analysis. Rheumatology 51 (2012), 100–109.
165. Mukhtyar, C., Lee, R., Brown, D., et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68 (2009), 1827–1832.
166. Exley, A.R., Bacon, P.A., Luqmani, R.A., et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40 (1997), 371–380.
167. Monach, P.A., Warner, R.L., Tomasson, G., et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 72 (2013), 1342–1350.
168. Ishizaki, J., Takemori, A., Suemori, K., et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther, 19, 2017, 218.
169. O'Reilly, V.P., Wong, L., Kennedy, C., et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27 (2016), 2906–2916.
170. Jayne, D.R.W., Bruchfeld, A.N., Harper, L., et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28 (2017), 2756–2767.
171. Stone, J.H., Merkel, P.A., Spiera, R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
172. Specks, U., Merkel, P.A., Seo, P., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369 (2013), 417–427.
173. Geetha, D., Specks, U., Stone, J.H., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26 (2015), 976–985.
174. Unizony, S., Villarreal, M., Miloslavsky, E.M., et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75 (2016), 1166–1169.
175. Miloslavsky, E.M., Lu, N., Unizony, S., et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets. Arthritis Rheumatol 68 (2016), 2945–2952.
176. Jones, R.B., Tervaert, J.W., Hauser, T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (2010), 211–220.
177. Jones, R.B., Furuta, S., Tervaert, J.W., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74 (2015), 1178–1182.
178. Karras, A., Pagnoux, C., Haubitz, M., et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76 (2017), 1662–1668.
179. Roccatello, D., Sciascia, S., Rossi, D., et al. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget 8 (2017), 52072–52077.
180. Jones, R.B., Ferraro, A.J., Chaudhry, A.N., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60 (2009), 2156–2168.
181. Rhee, E.P., Laliberte, K.A., Niles, J.L., Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5 (2010), 1394–1400.
182. Cartin-Ceba, R., Golbin, J.M., Keogh, K.A., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64 (2012), 3770–3778.
183. Roubaud-Baudron, C., Pagnoux, C., Meaux-Ruault, N., et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39 (2012), 125–130.
184. Smith, R.M., Jones, R.B., Guerry, M.J., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64 (2012), 3760–3769.
185. Guillevin, L., Pagnoux, C., Karras, A., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 (2014), 1771–1780.
186. Roccatello, D., How I treat” autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 16 (2017), 995–998.
187. Wilkinson, N.M., Page, J., Uribe, A.G., et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 34 (2007), 224–226.
188. Cabral, D.A., Canter, D.L., Muscal, E., et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an ARChiVe Cohort Study. Arthritis Rheumatol 68 (2016), 2514–2526.
189. Eleftheriou, D., Melo, M., Marks, S.D., et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology 48 (2009), 978–986.
190. James, K.E., Xiao, R., Merkel, P.A., et al. Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clin Exp Rheumatol 35:suppl 103 (2017), 202–208.